Navigation Links
Detection of Malignant Breast Tumors Made Simpler and More Effective

Scientists linked with Harvard Medical School claim the discovery of a simpler method to distinguish benign breast tumors from malignant ones.//

Harvard’s Kumar R. Bhushan, Ph.D., who led the chemistry group that participated in the research, described details of the new technique today at the 233rd national meeting of the American Chemical society, the world’s largest scientific society.

When used with a non-invasive imaging method that relies on harmless light instead of X-rays, the contrast agent could help doctors diagnose disease within minutes and determine where biopsies are needed.

“Because this agent is highly selective in targeting the product of malignant tumors, this approach may prove most useful for monitoring women who have dense breast tissue, or those who are at a higher-than-average risk for developing a malignant breast tumor,” Frangioni says.

For screening applications, the new technique most likely would be used to supplement, not replace, mammography, according to Frangioni. But the two methods used together, he says, may potentially catch more cancers than mammography alone.

Mammography is still considered the “gold standard” for early detection of breast cancer, but the method often gives false positives, requiring additional screenings and painful biopsies for patients. In addition, studies show that traditional mammograms may miss 10 percent to 20 percent of breast cancers, especially if the tumor is buried in dense tissue.

About half of women under 50 and a third of older women have naturally dense breast tissue, making it harder to distinguish between healthy tissue and questionable masses in mammograms, Frangioni says.

The new agent works by binding to micro-calcifications produced in breast cancers. Though scientists can’t explain exactly why these calcifications occur, studies show that the calcifications in malignant breast tumors contain a higher proportion of a particular calcium salt called hydroxyapatite. In benign tumors, the predominant calcium salt is calcium oxalate.

“By homing in on hydroxyapatite, we can target these malignant cells with a high degree of specificity, and that has the potential to improve the patient’s outcome,” Frangioni says.

The contrast agents are designed using a combination of bisphosphonate, a type of drug used to strengthen bone, with a near-infrared fluorophore. When used with optical tomography, an imaging method that transmits near-infrared light through the body, doctors can reconstruct a three-dimensional image of tissues deep inside the breast, highlighting areas where malignant tumors appear.

The agent also may be used during surgery to pinpoint the location of hydroxyapatite, and therefore the breast cancer cells themselves, Frangioni notes.

His group began working to develop agents to target hydroxyapatite six years ago, but efforts were stalled by the inability to manufacture large quantities of the agent. “It was a chemical catch–22,” he says. “Bisphosphonates are insoluble in anything but water, but to prepare large quantities of the substance for our studies, we need to perform the reaction in the absence of water.”

Future studies will focus on translating the new compound to the clinic for human testing. It will likely be a few years before the compound is ready for use in human trials, according to Frangioni.

Source-Eurkalert
ANN
'"/>




Related medicine news :

1. Detection of Cancer
2. Early Detection Of Prostate Cancer
3. Early Detection of Lung Cancer
4. Early Detection of Prostate Cancer
5. Early Detection Of Facial Abnormalities in a Fetus
6. Early Detection Of Lung Cancer
7. Early Detection Of Breast Cancer
8. Do Not Neglect Your Abdominal Pain/ Swelling - Help Your Doctor In Early Cancer Detection
9. Patient Negligence - Significant Problem In The Early Detection Of Breast Cancer
10. Digital Mammogram For Detection Of Breast Cancer In Women With Dense Breasts
11. Early Detection Of Prostate Cancer For Complete Recovery From Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/5/2016)... ... December 05, 2016 , ... ... and relationship-marketing firm, announced today that nominations will be accepted from December ... (ISE®) Central Awards. , Awards include the Information Security Executive® of the ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... Meeting through tomorrow, December 6th, sparks a conversation about epilepsy, bearing down on ... in 26 people will be diagnosed with epilepsy within their lifetime. With such ...
(Date:12/5/2016)... , ... December 05, 2016 ... ... interoperability, today announced that the company will provide alerting technology to Central ... been recently awarded $1.7 million in federal funds as the sole sub-recipient ...
(Date:12/5/2016)... ... December 05, 2016 , ... Dr. Barry M. Weintraub, one ... Surgery, who recently participated in the 36th Annual Cutting Edge Aesthetic Symposium at the ... techniques for getting that perfect, yet natural-looking, nose. Dr. Weintraub, who is world-renowned for ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... Officer for the Florida Hospital West Florida Region. McGuinness brings experience in executive ... and engaging staff, physicians and leaders. , In her new role, that officially ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec. 5, 2016  BD (Becton, Dickinson ... global medical technology company, will demonstrate an enhanced technology ... management technologies, including the company,s leading Pyxis™ and Alaris™ ... Pharmacists (ASHP) 2016 Midyear Meeting being held in ... While national data show that approximately 68 ...
(Date:12/5/2016)... Research and Markets has announced the addition of the "Global ... and Demand Forecast to 2022" report to their offering. ... , , ... market is expected to grow at a CAGR of 4.5% during ... witnessing high growth, due to growing female geriatric population and increasing ...
(Date:12/5/2016)... England , December 5, 2016 ... Transitions to Deputy Chairman   ... on selectively targeting deubiquitylating enzymes (DUBs) to treat cancer, neurodegenerative ... has been appointed as non-executive Chairman, effective January 1 st ... of Mission Therapeutics as a non-executive Director in July 2015. ...
Breaking Medicine Technology: